A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This phase 1/2 study will evaluate the safety, tolerance and dose of BM7PE treating patients with colorectal cancer who have progressed to standard cell therapy or cannot tolerate such therapy. The study starts as a phase 1 study with the aim of assessing the final dose for this group of patients. Based on the results, the study will continue into a phase 2. The phase 2 study aim to examine overall survival ≥ 9.3 months.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oslo University Hospital

Criteria

Inclusion Criteria:

• Histologically verified adenocarcinoma of colon or rectum

• Ambulatory with an ECOG performance status 0-1

• At least 18 years of age

• Progressive disease on or last line of standard chemotherapy or intolerance to further chemotherapy

• Laboratory values as the following: ANC, Platelets, Hb, Creatinine, Bilirubin, ASAT, ALAT, Albumin levels, INR

• Signed informed consent and expected cooperation of the patients for the treatment, and follow-up must be obtained and documented according to ICH GCP, and national/local regulations

Exclusion Criteria:

• History of prior metastatic disease the last 3 years

• History of CNS or bone metastases

• Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia

• Chemotherapy/radiation therapy or major surgery within the last 4 weeks before start of treatment

• Alcohol or drug abuse

• Any reason why, in the opinion of the investigator, the patient should not participate

• Has a known history of Human Immunodeficiency Virus (HIV)

• Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected)

• Is pregnant or breastfeeding, or expecting to conceive or father children within the project duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.